

ISCTM PRECISION MEDICINE SURVEY RESULTS

Doug Feltner, M.D.

Aidan Power, M.D.


And the ISCTM members who responded to the survey

Goals for the Workshop

- 1) Review the results of the survey. Better understand why people answered as they did.
- 2) Develop suggested recommendations for what ISCTM should do to support the development of precision medicines for CNS disorders
- 3) Identify most promising indications and technologies for precision medicines in CNS.


Experience with Precision Medicines

Q1. Please indicate which statement(s) most accurately describes your experience in the research and development of precision medicines:





Organization working on CNS precision meds?

Q2. Is your organization currently engaged in the discovery or development of precision medicines for CNS disorders?




Organization working on non-CNS precision meds?

Q3. Is your organization currently engaged in the discovery or development of precision medicines for non-CNS disorders?



Your current involvement with precision meds

Q4. Please choose the statement that best describes your level of intended participation and interest in precision medicine.



- a. I am currently spending or plan to spend more than half of my time on precision medicine.
- b. I currently work or want to work on precision medicine projects less than half of my time.
- c. I do not work on precision medicines, but would like to learn more about them.
- d. I am not interested in precision medicine.

Indications suited for precision med discovery/development (# positive votes)

Disorder	Excellent	Good	Fair	Poor
Highest Rated				
Alzheimers	15	13	3	2
Fragile X	12	11	3	2
Autism	9	13	7	4
Schizophrenia	9	10	9	4
Parkinson's	8	13	9	2
Lowest Rated				
Smoking	3	8	11	10
PTSD	1	8	11	9
Insomnia	5	6	9	10
Alcohol	1	7	15	6

Q5: Please rank the following therapeutic indications for whether you think they are Excellent, Good, Fair, Poor, or not candidates for the discovery and development of a precision medicine.

Most promising disorders (Top 2) and most chosen co-diagnostics

Disorder	# Votes for disorder	Diagnostic #1	Diagnostic #2	Diagnostic #3
Alzheimers	13	Combined-8	Neuroimage-7	Multigene-6 Multiprotein-6
Schizophrenia	9	Combined-6	Multigene-4	Cognition-3
Parkinson's	7	Combined-7	Single gene-4	Neuroimage-4
Fragile X	6	Multigene-5	Combined-4	Multiprotien-2 mRNA-2
MDD	5	Combined-5	Multigene-2	Multiprotein-2 cognition-2
ALS	4	Combined-4	SG,SP, MG, MP-all 2	
Insomnia (1), Substance abuse (1) Smoking (0), Alcoholism (0),PTSD (0),				


Most commonly selected co-diagnostics

Co-Diagnostic	Number of positive Responses	Response % (# responses/64)
Multigene	31	48%
Combination	30	47%
Multiprotein	18	28%
Cognitive Measures	17	27%
Neuroimaging	16	25%
mRNA (one or more)	14	22%
Don't know	13	20%

Each co-Diagnostic could be selected a maximum of 64 times.



Should pharma work on precision meds?

Q8. In general, do you believe that pharmaceutical companies should try to discover and develop precision medicines?




Plan to participate in workshop?

Q9. Do you plan to participate in the precision medicine workshop at the Autumn 2012 ISCTM meeting where this survey will be first discussed?



Precision medicine mission for workgroup?

Q10. If ISCTM were to form an ongoing precision medicine working group, which of the following should be a part of its mission (rank in order of importance to mission - 4 being most important)?



PM workgroup work focus?

Q11. What should be the work and output of an ongoing precision medicine workgroup? (rank in order of importance - 3 being most important)

